

DRAFT AGENDA

Translational Advances in Cancer Prevention Agent Development (TACPAD)

4th Biennial Virtual Meeting

Sponsored by the Division of Cancer Prevention, NCI

DATE: September 28-30, 2026

Times listed are for Eastern Daylight Savings Time

Day 1, September 28th (11:00 AM to 4:30 PM)

- | | |
|------------------------------|--|
| 11:00-11:10 AM | Welcome
Altaf Mohammed, Ph.D., Meeting Co-Organizer, DCP/NCI
Brian Cholewa, Ph.D., Meeting Co-Organizer, DCP/NCI |
| 11:10-12:00 PM | Plenary Talk
Lori Minasian, MD., Deputy Director, DCP/NCI
NCI Division of Cancer Prevention: Overview and Research Opportunities |
| 12:00-3:00 PM | Session I
Emerging Targets, Vaccines and Immunomodulatory Agents for Cancer Prevention
<i>Co-Chairs:</i> Nicholas Arpaia and Anda Vlad |
| 20 minutes talk, 10 min Q&As | |
| 12:00-12:30 PM | Speaker 1: Sarah Blagdon, BSc, FRCP, PhD, University of Oxford
LungVax vaccine for lung cancer prevention |
| 12:30-1:00 PM | Speaker 2: Nicholas Arpaia, Ph.D., Columbia University Irving Medical Center
Programmable probiotics for personalized cancer immunotherapy and immunoprevention |
| 1:00-1:30 PM | Lunch |
| 1:30-2:00 PM | Speaker 3: Robert Samstein, MD, Ph.D., Icahn School of Medicine at Mount Sinai
Immune determinants modulating cancer development in Lynch Syndrome |
| 2:00-2:30 PM | Speaker 4: Jennifer Bailey, Ph.D., University of Texas HSC Houston
Targeting the A2B Adenosine Receptor for Immunoprevention of Pancreatic Cancer |
| 2:30-3:00 PM | Speaker 5: McGuire, Andrew, PhD, Fred Hutchinson Cancer Center
Manufacture of Epstein-Barr Virus Vaccine |
| 3:00-3:30 PM | Break |

3:30-4:30 PM **Early Investigator Flash Talks**

Co-Chairs: Altaf Mohammed and John Clifford

10 minutes talk, 5 min Q&As

3:30-3:45 PM Speaker 1: Alexander Raufi, MD
ONC201 for Colorectal Cancer Prevention

3:45-4:00 PM Speaker 2: Nicholas Collins, Ph.D., Weill Cornell Medicine
Caloric restriction enhances the function of the immune system

4:00-4:15 PM Speaker 3: Preshita P. Desai, B. Pharm, PhD; Western University of Health Sciences
The Perfect Pair: Engineering Drug Synergy and Nano Drug Delivery Precision for Smarter Cancer Prevention

4:15-4:30 PM Speaker 4: Venkateshwar Madka, Ph.D., University of Oklahoma
Bladder cancer prevention

Adjourn

Day 2, September 29th (11:00 AM to 5:00 PM)

Session II: Molecularly Targeted Novel Agents for Cancer Prevention and Interception

Co-Chairs: Michael Buszczak and Asad Umar

20 minutes talk, 10 min Q&As

11:00-11:30 AM Speaker 1: Clara Curiel, MD., University of Arizona
Investigating novel targets for topical immunoprevention of skin cancer

11:30-12:00 PM Speaker 2: Ming You, M.D., Ph.D., Houston Methodist Research Institute
Mitochondria-targeted honokiol for lung cancer interception

12:00-12:30 PM Speaker 3: Michael Buszczak, Ph.D., UT Southwestern Medical Center
Discovery and Development of Natural Products for Liver Cancer Prevention

12:30-1:00 PM Speaker 4: TBD

1:00-1:30 PM Speaker 5: Chinthalapally V. Rao, Ph.D., University of Oklahoma
LFA9 for Colon Cancer Prevention and Interception: Discovery to Clinic

1:30-2:00 PM Lunch

Session III: Clinically relevant alternative models for cancer prevention

Co-Chairs: Brian Cholewa and Kajal Biswas

20 minutes talk, 10 min Q&As

- | | |
|--------------|--|
| 2:00-2:30 PM | Speaker 1: David Tuveson, PhD, Cold Spring Harbor Laboratory
Organoids for Cancer Prevention, Interception and Treatment |
| 2:30-3:00 PM | Speaker 2: David Beebe, Ph.D. University of Wisconsin
Microfluidics in biomedical research: lab-on-a-chip microtechnologies |
| 3:00-3:30 PM | Speaker 3: Joseph C. Wu, MD, PhD., Stanford University School of Medicine
NAMs and drug screening |
| 3:30-4:00 PM | Speaker 4: Yurong Song, PhD., Leidos
Organoids for cancer prevention |
| 4:00-5:00 PM | Meet with the NCI Program Staff <ul style="list-style-type: none">• Biomarkers – Indu Kohaar and Sydney Fu• Prevention/Interception – John Clifford and Anda Vlad• Clinical trials – Goli Samimi and Eileen Diamond |

Adjourn

Day 3, September 30th (11:00 AM to 4:30 PM)

Session V: Cancer Prevention-Interception Clinical Trials

Co-Chairs: Eduardo Vilar-Sanchez and Goli Samimi

20 minutes talk, 10 min Q&As

- | | |
|----------------|--|
| 11:00-11:30 AM | Speaker 1: Goli Samimi, Ph.D., DCP/NCI
<i>Overview of DCP Supported Clinical Trials</i> |
| 11:30-12:00 PM | Speaker 2: Eduardo Vilar-Sanchez, MD, Ph.D., MD Anderson Cancer Center
Nous 209 vaccine trial |
| 12:00-12:30 PM | Speaker 3: Seema Khan, MD, Northwestern Feinberg School of Medicine
RENAISSANCE trial for breast cancer prevention |
| 12:30-1:00 PM | Speaker 4: Juan Chipollini, MD; The University of Arizona
Apalutamide low dose trial for prostate cancer prevention |
| 1:00-1:30 PM | Speaker 5: Britt K Erickson, MD; University of Minnesota
Daily Exemestane in Women with Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer |

1:30-2:00 PM **Break**

Session IV: Panel Discussion

Biomarkers as intermediate end points for cancer prevention clinical trials

Co-Chairs: Brandy Heckman-Stoddard

2:00-2:25 PM TBD

2:25-2:50 PM Brandy Heckman-Stoddard, Ph.D., DCP/NCI
Status on current intermediate end points for cancer prevention clinical trials

2:50-4:30 PM **Panel Discussion**

Closing Remarks and Adjourn

Brian Cholewa, Ph.D., Meeting Co-Organizer, DCP/NCI

Altaf Mohammed, Ph.D., Meeting Co-Organizer, DCP/NCI